Skip to main content
2026 CRT Conference Main banner

CRT 2026

Atherosclerosis and Lipids

Session:: Atherosclerosis and Lipids Summit

Panel Discussion | Our Understanding on the Pathophysiology and Mechanism of Atherosclerosis and the New Therapeutic Options

Sunday, March 8, 2026
2:26 PM - 2:45 PM EST
Location: Monroe

    Moderator(s)

  • Takashi Akasaka, MD, PhD

    Senior Consultant
    Nishinomiya Watanabe Cardiovascular Cerebral Center
    Nishinomiya, Hyogo, Japan

    Disclosure(s): Abbott Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 18, 2025)

  • Rasha Al-Lamee, MA, MD, PhD

    Interventional Cardiology Consultant
    Imperial College London
    London, England, United Kingdom

    Disclosure information not submitted.

  • Renu Virmani, MD

    President
    CVPath Institute, Inc.
    Gaithersburg, Maryland, United States

    Disclosure information not submitted.

    • Panel Discussant(s)

  • Usman Baber, MD, MS

    Professor of Medicine
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma, United States

    Disclosure information not submitted.

  • Charles German, MD, MS, FAHA, FASPC

    Assistant Professor
    Georgetown University

    Disclosure(s): No financial relationships to disclose

  • Ramzi Khamis, MB ChB PhD FRCP FESC

    Professor of Cardiology. Consultant Cardiologist.
    Imperial College London and Imperial College Healthcare NHS Trust
    London , England, United Kingdom

    Disclosure(s): No financial relationships to disclose

  • Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

    Professor
    Johns Hopkins
    Reisterstown, Maryland, United States

    Disclosure(s): Amgen, Arrowhead, Chroma, HeartFlow, Kaneka, Merck, NewAmsterdam, Novartis, Pfizer, Sanofi, and Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Owner/Co-Owner Founder/Co-Founder (Ongoing), Stock-privately held company (Ongoing)

  • Paul M. Ridker, MD

    Director, Center for Cardiovascular Disease Prevention
    Brigham and Womens Hospital
    Brookline, Massachusetts, United States

    Disclosure information not submitted.

  • Robert S. Rosenson, MD

    Director of Metabolism and Lipids
    Mount Sinai Health System
    New York, New York, United States

    Disclosure information not submitted.

  • Allen J. Taylor, MD

    Chairman of Cardiology
    MedStar Heart and Vascular Institute
    Washington, District of Columbia, United States

    Disclosure(s): Heartflow Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):
Takashi Akasaka, MD, PhD: Abbott Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 18, 2025)
Charles German, MD, MS, FAHA, FASPC: No financial relationships to disclose
Ramzi Khamis, MB ChB PhD FRCP FESC: No financial relationships to disclose
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen, Arrowhead, Chroma, HeartFlow, Kaneka, Merck, NewAmsterdam, Novartis, Pfizer, Sanofi, and Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Owner/Co-Owner Founder/Co-Founder (Ongoing), Stock-privately held company (Ongoing)
Allen J. Taylor, MD: Heartflow Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)